Trial Profile

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASP 1570 (Primary) ; Bevacizumab (Primary) ; Docetaxel (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions
Sponsors Astellas Pharma Global Development

27 Dec 2024 Protocol amended to exclude one arm; Experimental: ASP1570 Monotherapy Tumor Specific Dose Expansion - Response-triggered Tumor (Part 2)
27 Dec 2024 Planned number of patients changed from 330 to 310.
27 Dec 2024 Planned End Date changed from 31 Dec 2027 to 31 May 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com